Mesoblast揭晓了林业发展局批准的Ryoncil 治疗儿童严重血液移植并发症。 Mesoblast unveils FDA-approved Ryoncil for treating a severe blood transplant complication in children.

Mesoblast有限公司新近获得林业发展局批准的Ryoncil(remestemcel-L)正在一次重大医疗会议上展示。 Mesoblast Limited's newly FDA-approved Ryoncil® (remestemcel-L) is being showcased at a major medical conference. 这种治疗是美国首个批准用于治疗两个月及以上儿童的类固醇耐药性急性移植对宿主病的中细胞层细胞治疗. This treatment is the first mesenchymal stromal cell therapy approved in the U.S. for steroid-refractory acute graft-versus-host disease in children aged two months and older. Mesoplast正在宣传药物的好处,并在活动期间与保健服务提供者分享临床结果。 Mesoblast is promoting the drug's benefits and sharing clinical results with healthcare providers at the event.